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Background: The apicomplexan hemoparasite Theileria equi is a causative agent of equine piroplasmosis,
eradicated from the United States in 1988. However, recent outbreaks have sparked renewed interest in treatment
options for infected horses. Imidocarb dipropionate is the current drug of choice, however variation in clinical
response to therapy has been observed.
Methods: We quantified the in vitro susceptibility of two T. equi isolates and a lab generated variant to both
imidocarb dipropionate and a bumped kinase inhibitor compound 1294. We also evaluated the capacity of in vitro
imidocarb dipropionate exposure to decrease susceptibility to that drug. The efficacy of imidocarb dipropionate for
clearing infection in four T. equi infected ponies was also assessed.
Results: We observed an almost four-fold difference in imidocarb dipropionate susceptibility between two distinct
isolates of T. equi. Four ponies infected with the less susceptible USDA Florida strain failed to clear the parasite despite
two rounds of treatment. Importantly, a further 15-fold decrease in susceptibility was produced in this strain by
continuous in vitro imidocarb dipropionate exposure. Despite a demonstrated difference in imidocarb dipropionate
susceptibility, there was no difference in the susceptibility of two T. equi isolates to bumped kinase inhibitor 1294.
Conclusions: The observed variation in imidocarb dipropionate susceptibility, further reduction in susceptibility caused
by drug exposure in vitro, and failure to clear T. equi infection in vivo, raises concern for the emergence of drug
resistance in clinical cases undergoing treatment. Bumped kinase inhibitors may be effective as alternative drugs for
the treatment of resistant T. equi parasites.
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susceptibilityBackground
Theileria equi, one of the two causative agents of equine
piroplasmosis, is a tick-transmitted hemoprotozoan pa-
rasite classified within the phylum Apicomplexa. The
United States has been considered free of equine piro-
plasmosis for several decades, however the occurrence
of multiple U.S. outbreaks in recent years has caused a
resurgence of interest in effective treatment options. In-
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unless otherwise stated.with resolution of clinical signs [1-3]. Strict federal regu-
lations for the elimination of infected horses have been
established in an attempt to maintain piroplasmosis-free
status in the U.S., requiring T. equi positive horses to be
euthanized, permanently quarantined, exported to the
country of origin, or treated under the current USDA-
ARS-APHIS treatment program [4,5]. This program is
currently the only federally-sanctioned option for treat-
ment in the U.S., as full elimination of parasites from the
host must be verified in order for treated horses to no lon-
ger be considered potential reservoirs of infection [5].
For most apicomplexan parasitic pathogens, the goal of
treatment is to minimize the clinical impact of disease.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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erable challenge, particularly with organisms such as T.
equi which causes persistent infection [3]. Imidocarb di-
propionate (IMD) is a dicationic diamidine of the carbani-
lide series of antiprotozoal compounds, and is the drug
most commonly used to treat equine piroplasmosis caused
by both T. equi and Babesia caballi. In a recent major out-
break localized in Texas [6], IMD successfully cleared over
163 naturally infected horses of T. equi (Dr. Angela Pelzel,
USDA-APHIS, personal communication) [4,5]. However,
variation in response to treatment with an identical IMD
protocol has been observed in both natural and experi-
mental T. equi infection [4,7-10], with treatment failure
characterized by parasite persistence and recrudescence of
parasitemia following discontinuation of treatment. The
identification of drug resistance in other apicomplexan
parasites [11-13] indicates drug resistance is likely an im-
portant factor in T. equi treatment failures. In particular,
the human malarial agent Plasmodium falciparum has ex-
hibited continuously evolving multidrug resistance, ne-
cessitating continued development of novel antimalarial
drugs for effective treatment. Importantly, failure of treat-
ment with previously effective drug protocols is almost in-
variably associated with decreased in vitro susceptibility to
the treatment drug [11,14].
Many drugs have been assessed in vitro for efficacy
against T. equi [15-21]; however a large number of these
are not biologically relevant or feasible for use in horses.
Although IMD is commonly used clinically, suscepti-
bility has never been evaluated in vitro for T. equi nor
compared between parasite strains. Importantly, the po-
tential impact of IMD exposure on the susceptibility of
T. equi to this drug, a known factor in the development
of drug resistance in many other organisms [14,22-27],
has not been investigated.
Given the scarcity of treatment options for T. equi and
the potential for drug resistance, evaluation of alterna-
tive and novel drugs is necessary. Bumped kinase inhibi-
tors (BKIs) are a group of experimental compounds
currently being investigated for in vitro and in vivo efficacy
against malaria [28,29], toxoplasmosis [30,31], cryptospor-
idiosis [31,32], and other protozoal diseases [33]. The BKIs
selectively inhibit apicomplexan calcium-dependent pro-
tein kinases (CDPKs), which are critical for multiple para-
sitic physiological functions including parasite motility
and invasion as well as in secretory pathways and rep-
lication [28]. Importantly, these CDPKs are absent in
vertebrates, making them excellent anti-apicomplexan
chemotherapeutic candidates [34]. Specifically, BKIs are
competitive inhibitors of ATP-binding, and gatekeeper
residue size appears to be a major factor in the selectiv-
ity of BKIs. These residues in apicomplexan CDPKs are
small, typically glycine, serine, or threonine [28,34],
which allow access to the ATP-binding pocket for BKIsto bind and inhibit apicomplexan CDPKs. Although
CDPKs are not present in mammals, binding of most
other mammalian kinases by BKIs is prevented by gate-
keeper amino acid residues with large side chains that
occlude access to the ATP-binding pocket. Therefore,
the BKIs do not inhibit the proliferation of mammalian
cells, and have been shown to be non-toxic in rodents
[28,29,32].
In the present study, we evaluated the in vitro growth
inhibitory effects of IMD against two isolates of T. equi,
as well as a variant that was exposed in vitro to the drug.
We also describe four ponies infected experimentally
that failed to clear T. equi despite two rounds of IMD
treatment following the established protocol (4 mg/kg,
IM, q72 hrs for four doses) [7]. We then evaluated the
in vitro efficacy of a novel bumped kinase inhibitor, BKI
compound 1294, against two T. equi isolates with differ-
ent degrees of susceptibility to IMD. This BKI com-
pound was equally effective against both T. equi isolates,
including the variant exposed in vitro to IMD. The re-
sults of this work should have implications in the design




For HL2A-FBS and –NHS culture media, HL-1 and
HEPES were obtained from Fisher Scientific (Waltham,
MA), HB101 supplement from Irvine Scientific (Santa
Ana, CA), L-glutamine and AlbuMax from Gibco (Grand
Island, NY) and penicillin/streptomycin and gentamicin
from Sigma-Aldrich (St. Louis, MO). Hydroethidine was
acquired from Invitrogen (Carlsbad, CA) as a 5 mM so-
lution solubilized in DMSO. Imidocarb dipropionate
(Imizol®, Merck, Millsboro, DE) at 344 mM (120 mg/mL)
was utilized as the stock solution for all IMD assays and
diluted in medium to reach experimental concentrations
each day for use in the parasite growth inhibition assay
described below. Bumped kinase inhibitor compound
1294 was generated as described [35], dissolved in DMSO
at 20 mM, and then diluted in medium as above for use in
the BKI 1294 growth inhibition assays.
Evaluation of Theileria equi CDPK sequence
Relevant amino acid sequences of BKI-binding CDPK
proteins from other apicomplexans [33] including P.
falciparum (PfCDPK1 [GI:124801388]), Babesia bovis
(BbCDPK4 [GI: 154796736]), and T. gondii (TgCDPK1
[GI:255917998]) were obtained from GenBank and
BLASTed (blastp, NCBI) against amino acid sequences
predicted in the T. equi genome (GenBank accession
number: ACOU00000000) in order to identify the T. equi
ortholog. These sequences were then aligned and analyzed
using ClustalW and BoxShade programs.
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The USDA Florida strain of T. equi (FL) [36,37] was ob-
tained as a subculture from ongoing USDA research cul-
tures. Cultures were initially grown in a microaerophilic
environment (5% O2) in modified HL2A-FBS medium
[38] with 10 mM hypoxanthine, 200 U/mL penicillin,
and 200 μg/mL streptomycin added. Over time, the cul-
tures were adapted to ambient O2 in a 5% CO2 37°C in-
cubator and medium was converted from modified
HL2A-FBS to modified HL2A-NHS (substituting normal
horse serum for fetal bovine serum). Cultures were
maintained in 24 well plates with an erythrocyte con-
centration of 10% in 1300 μL total well volume and
split 1:4 every other day, with 1000 μL of medium
changed on intervening days.
A novel T. equi isolate (TX) was obtained from a para-
sitemic horse as a part of a separate previous study [4]
and adapted into culture. Briefly, an EDTA-anticoagulated
whole blood sample was collected and centrifuged at 800
g for 30 minutes. The plasma and leukocytes were dis-
carded, and the erythrocytes washed three times in an
equivalent volume of VYMs buffer, centrifuging as before.
These infected erythrocytes were then placed in one well
of a 24 well plate with 1000 μL of media at a 1:1 ratio with
uninfected normal horse erythrocytes (60 μL of each). The
plate was initially placed in a 37°C incubator with 5% O2,
5% CO2, and 90% N2 gas, however following successful
culture initiation, TX was subsequently adapted to ambi-
ent O2 in a standard 5% CO2 incubator and maintained as
for the FL strain.
In vitro parasite growth inhibition assay
Initial IMD concentrations to be used in the assay were
determined based on the pharmacokinetics of the drug
in horses [39] and the in vitro susceptibility of other or-
ganisms to the drug [22,40,41]. To evaluate the dyna-
mics of parasite growth during IMD exposure and to
determine the appropriate incubation time for the assay,
the FL strain was cultured in a 24-well plate for 72 hours
with assessment of parasite growth via flow cytometry
(below) and one mL medium change every 24 hours.
Serial dilutions of IMD were tested in triplicate ranging
from 1 nM to 775 nM, with a target starting percent
parasitized erythrocytes (PPE) for all wells of 0.25-0.5%.
Based on these results, it was determined that the as-
say should be performed over 72 hours, starting at a low
initial PPE. Further assays were performed in a 96-well
plate, with a final erythrocyte concentration of 9% and
target starting PPE of approximately 0.3%. Two-fold ser-
ial dilutions of IMD ranged from 2.7 nM to 344 nM,
and triplicate samples for each concentration, including
infected untreated controls, were evaluated. Triplicate
wells of normal uninfected erythrocytes were also in-
cluded as a control comparison. For assay initiation, 2xdrug concentrations were prepared, with 100 μL of the
appropriate concentration placed into each well with
100 μL of normal medium and 20 μL of RBCs to reach
the final 1× drug concentration for the assay and ap-
proximately 9% RBC concentration in each well. At 24
and 48 hours, 160 μL of medium containing the appro-
priate 1× drug concentration was changed in each well,
with plain medium used for controls. The assay was then
evaluated at 72 hours. Complete growth inhibition was
considered to be achieved when the PPE remained at the
starting level of 0.3-0.5% after 72 hours, indicating no
active parasite growth.
The chemical structure of BKI 1294 has been previ-
ously published [30]. Drug concentrations tested for BKI
1294 included 0.3 μM, 3 μM, 6 μM, 9 μM, 12 μM, and
30 μM. Assay procedure was otherwise identical to that
for IMD.
Flow cytometric evaluation of parasite growth
After 72 hours, all samples were transferred to a 96 well
V-bottom plate to be stained with hydroethidine. Cells
were centrifuged at 500 g at room temperature, and the
culture medium supernatant discarded. They were then
washed in 150 μL of 1× PBS per well and centrifuged as
before. Stock 5mM hydroethidine in anhydrous DMSO
was diluted to 20 μg/mL in 1× PBS and added at to all
samples (including normal erythrocytes) at 100 μL per well.
Samples were incubated for 15 minutes at 37°C in 5% CO2
in the absence of light, and 100 μL of plain 1× PBS was
added at the conclusion of the incubation prior to centrifu-
gation. After removal of the supernatant, the cells were re-
suspended in 200 μL of 1× PBS. Fifty μL of each sample
was then diluted into approximately two mL of 1× PBS
containing 0.2% sodium azide for flow cytometric analysis.
Cell suspensions were evaluated using a FACSCaliber
flow cytometer equipped with CellQuest computer soft-
ware (Becton Dickinson Immunocytometry Systems, San
Jose, CA) on a Macintosh computer. The inclusion gate
was based on the forward and side scatter features of
uninfected erythrocytes stained with hydroethidine, and
50,000-150,000 events per sample were collected. Ethidium
bromide fluoresces in the FL-2 channel, therefore argon-
laser fluorescence excitation at 488 nm and emission at
585 nm (range 563–607 nm) were used for analysis in log
Fl 2 data mode. Fluorescent profiles were recorded for later
analysis with FCS Express software (De Novo software, Los
Angeles, CA). Quadrant gating of generated dot plots (Fl-2
vs. side scatter) was based on stained uninfected erythro-
cyte controls to delineate between infected and uninfected
cell populations.
Determination of IC50 and IC90 values
The PPE of each well was determined based on the per-
centage of the cell population characterized as RBCs that
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concentration and controls was calculated by averaging
the PPE of all three triplicate wells. Individual PPE
values that deviated from the other replicates by >0.5%
were considered outliers and eliminated from data evalu-
ation. Percent of maximum PPE was then calculated for
each concentration using the mean PPE value in com-
parison to the highest PPE obtained in the assay for a
given isolate. The 50% (IC50) and 90% (IC90) inhibitory
concentrations were determined by fitting the curves
with nonlinear regression using GraphPad Prism version
6.03 for Windows (GraphPad Software, La Jolla, CA).
Exposure of Theileria equi parasites to imidocarb
dipropionate in vitro
Exposure of the FL strain of T. equi to IMD was per-
formed via two different methods. The first method in-
volved pulse exposure, with parasites exposed at 28.7
nM (the approximate IC50 value determined previously)
for an initial period of 11 days, until growth had de-
clined to a PPE of less than 1.5%. Drug pressure was
then removed and the parasites were allowed to recover
for five days. They were then re-exposed to 28.7 nM for
24 hours. Subsequent 24 hour re-exposures of the pulse
exposure variant to increasing concentrations of IMD
were performed over the next two months, allowing suf-
ficient time for recovery between exposures, with the
final re-exposure at 172 nM (FL Exp variant 1). The
third method of FL IMD exposure involved continuous
exposure to increasing concentrations of IMD, starting
at the lowest previously determined IC50 of the strain
(24 nM) and gradually increasing up to 115 nM (FL Exp
variant 2).
The TX isolate was exposed continuously to 3.2 nM
IMD for 24 days and also to a higher concentration
(9.5 nM IMD) for a short period of time (11 days).
Infection and treatment of ponies with Theileria equi
Four naïve mixed-breed ponies, 1–2 years of age, were
experimentally infected with the USDA FL strain of T.
equi via Rhipicephalus microplus tick transmission as a
part of a separate research study, using previously pub-
lished methods [42]. All ponies were confirmed positive
for T. equi by nested PCR [4] and were initially treated
with IMD (4 mg/kg, IM, q72 hrs for four doses) at seven
months post-infection. Post-treatment infection status
was determined using nested PCR and cELISA [43]. Be-
cause this initial treatment failed to clear T. equi in each
of the four ponies, the same treatment regimen was re-
peated 18 months post-infection and the same follow-up
evaluations performed. All experiments involving animals
were carried out in accordance with the recommendations
in the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health and in conformancewith the United States Department of Agriculture animal
research guidelines, under a protocol approved by the
Washington State University Institutional Animal Care
and Use Committee (ASAF # 04163).Results
Imidocarb dipropionate treatment of ponies
experimentally infected with the USDA FL strain of
Theileria equi
Sixteen days following the first round of IMD treat-
ment (seven months post-infection), all four ponies ap-
peared to be negative for T. equi based on nested PCR
(Figure 1a). However, nested PCR was repeated at 17
months post-infection and all ponies were found to be
positive. After the second round of IMD treatment at
18 months post-infection, the ponies again appeared
negative for T. equi based on nested PCR performed
16 days post-treatment. However, re-evaluation 37 and
80 days (Figure 1b) after this second round of treat-
ment (19–20 months post-infection) confirmed that all
ponies again reverted to a positive state and that two
rounds of IMD treatment failed to clear infection.
Seropositivity was also confirmed at 14 and 20 months
post-infection by cELISA (data not shown).In vitro susceptibility of Theileria equi to imidocarb
propionate
Development of the in vitro parasite growth inhibition
assay using IMD for T. equi was successfully accom-
plished using the FL parasite strain, with evaluation of
the PPE for each sample using flow cytometry (Figure 2).
Regardless of the concentration of IMD, the PPE in all
wells doubled or tripled over the first 24 hours. By 48
hours, the growth dynamics across IMD concentrations
began to diverge, with parasite growth at higher concen-
trations leveling off and that at lower concentrations
continuing to increase until reaching a maximum of
7-8% PPE at 72 hours. Overall, the final PPE across
the range of drug concentrations reflected a dose-
dependent effect of IMD, with an IC50 of 24 nM
(Figure 2a). An IC90 could not be determined for this
strain, because even at the maximum drug concen-
tration (775 nM) the PPE still reached 1.2%, equiva-
lent to 15.4% of the growth of untreated parasites.
This indicated that the FL strain parasite population
more than doubled from the starting PPE of 0.5% even at
high IMD concentrations, reflecting a lack of complete
growth inhibition.
The TX isolate originating from the 2009 outbreak
[4,6] was consistently more susceptible to IMD than the
FL strain, with an IC50 of 6.4 nM; almost six-fold lower
than FL (Figure 3a). In addition, an IC90 of 26 nM could
be determined for the TX isolate, as it did not actively
Figure 1 Nested PCR detection of T. equi infection in ponies after failed IMD treatment. (a) 2% agarose gel showing results from packed
erythrocytes collected 16 days after the second round of IMD treatment. Lane 2: negative control erythrocytes from an uninfected horse (−).
Lanes 3, 4, 5, 6: erythrocytes from the four IMD treated ponies. Lane 7: positive control erythrocytes from a known infected horse showing the
200 bp T. equi ema-1 amplicon (+). (b) T. equi ema-1 amplicons from packed erythrocytes collected 80 days after the second round of IMD
treatment. Lanes 2, 3, 4, 5: erythrocytes from the four IMD treated ponies. Lane 6: negative control (−). Lane 7: positive control (+).
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at the starting level of 0.5%.
Imidocarb dipropionate exposure of Theileria equi and
the effect on IC50
Continuous exposure of the FL strain to increasing con-
centrations of IMD (up to 115 nM) increased the IC50 a
maximum of 15-fold in FL Exp variant 2 to 414 nM
(Figure 3b). Pulse exposure with IMD (up to 172 nM)
increased the IC50 in FL Exp variant 1 to a lesser degree,
approaching four-fold at 94 nM (Figure 3b). However,
this effect could not be duplicated in the TX isolate.
Despite repeated attempts to expose TX to IMD, the
IC50 remained the same at approximately 6 nM. Expos-
ure of TX to a higher concentration of IMD (9.5 nM) re-
sulted in irrevocable decline in culture PPE and eventual
death of all exposed parasites.
Gatekeeper residue of Theileria equi calcium-dependent
protein kinase
Due to the variability in response to IMD, alternative
drugs for treatment of T. equi were considered. The BKIcompounds were of interest, and therefore evaluation of
the T. equi transcriptome for an appropriate CDPK drug
target was undertaken. Amino acid sequence compa-
risons of the BKI-binding CDPKs in P. falciparum, B.
bovis, and T. gondii against the T. equi predicted trans-
criptome identified the same protein kinase domain-
containing protein (GI: 510911326) as the putative CDPK
ortholog in T. equi. Alignment of these four sequences re-
vealed a threonine gatekeeper residue in T. equi, consist-
ent with the small amino acid gatekeeper residues present
in comparison organisms (Figure 4), all of which are sus-
ceptible to BKI compounds [33].In vitro susceptibility of Theileria equi to the bumped
kinase inhibitor compound 1294
For BKI 1294, the IC50 of the FL Exp variant 1 and
the TX isolate were similar (4.212 μM and 3.887 μM
respectively) (Figure 5). Active parasite growth of both
isolates was completely inhibited at the highest drug con-
centrations, with PPE limited to the starting level of 0.3%



















































































Figure 2 Flow cytometric scatter plots depicting percent
parasitized erythrocytes (PPE). Representative samples from a 72
hour growth inhibition assay. Parasitized erythrocytes stained with
hydroethidine were detected in the FL-2 channel, and are
represented in the bottom right quadrant. (a) Normal uninfected
erythrocytes stained with hydroethidine (negative control). (b)
T. equi-infected erythrocytes incubated without imidocarb
dipropionate (IMD; positive control). (c) T. equi-infected erythrocytes
incubated with 2.76 μM IMD.
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(11.502 μM and 10.964 μM, respectively).
Discussion
Although the life cycle of T. equi in horses is biphasic,
with an early pre-erythrocytic schizogony within leuko-
cytes, this schizont stage is transient and does not ap-
pear to play a role in persistent infection of horses [42].
Instead, long term infection is perpetuated through in-
fection and proliferation of merozoites in erythrocytes,
making this merozoite stage most relevant for chemo-
therapeutic intervention. Therefore, erythrocyte cultures
of merozoites were used in this study to evaluate in vitro
susceptibility. The observed difference in IMD suscepti-
bility between isolates, with the IMD IC50 of the FL
strain almost six-fold higher than that of the TX isolate,
was consistent with variation in efficacy that has been
observed clinically. The overall success rate of IMD
treatment for horses infected with the TX isolate during
the 2009 outbreak was extremely high [4]. In contrast,
the USDA FL strain has been used in multiple experi-
mental settings to evaluate the efficacy of IMD in vivo,
with infected horses often failing to clear FL following
treatment with a protocol identical to that used in the
TX outbreak [7,8]. This situation was also observed in
the current study, with four FL-infected ponies failing
to clear infection despite two rounds of IMD treatment
at 4 mg/kg every 72 hours for 4 doses per round. In-
terestingly, the ponies appeared negative immediately
after treatment, with parasite growth suppressed by
IMD to the point that it could not initially be detected
even with the extremely sensitive nested PCR method,
which has been shown to detect a level of parasitemia
of 0.000006% [44].
Previous research has demonstrated the presence of
T. equi in the spleen of asymptomatic horses at times
where it was undetectable in the peripheral blood via
multiplex PCR [2]. Additionally, it is possible that the
level of parasitemia was simply lower than the detectable
limit, and that the small number of parasites surviving
drug treatment was still sufficient to allow continued
infection after a period of parasite recovery. The lack of
complete in vitro inhibition of FL is consistent with the
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Figure 3 Variable in vitro susceptibility to IMD among different T. equi isolates. Each point on the nonlinear regression curve represents
the mean percent of the maximum PPE determined in triplicate wells. IC50 is drug concentration resulting in 50% of the maximum PPE detected
in wells not containing drug. (a) Susceptibility of the USDA FL strain (red) and the TX isolate (purple). (b) Susceptibility of FL Exp variant 1
(purple) and FL Exp variant 2 (green).
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Figure 4 Amino acid alignment through the ATP-binding domains of calcium dependent protein kinases. Includes amino acid sequences
from P. falciparum (Pf), T. equi (Te), B. bovis (Bb), and T. gondii (Tg). The ATP-binding region is boxed, and the gatekeeper residues are shaded.
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parasite inhibition led to a resurgence of parasitemia
in vivo. This also raises further concern about the po-
tential for development of resistance in these IMD-
exposed surviving parasites.
The pharmacokinetics of IMD administered intramus-
cularly in horses demonstrates a maximum plasma con-
centration of 0.2 μg/mL (574 nM) at a dose of 2.4 mg/mL
[39]. Although this concentration greatly exceeds the IC50
of 24 nM observed for the FL strain in the present
study, this plasma concentration is maintained for only
2 hours in vivo and drops to undetectable levels (less
than 0.0125 μg/mL, or 36 nM) after 12 hours [39]. In















Figure 5 In vitro susceptibility of T. equi isolates to BKI compound 12
percent of the maximum PPE determined in triplicate wells. IC50 is drug co
not containing drug. Depicted results represent TX (purple) and FL Exp varexposed to IMD continuously at the tested concentra-
tions for 72 hours, and in the case of FL, actively grew
despite exposure to high concentrations of drug.
It has been postulated that a reservoir effect exists for
IMD in vivo, as the drug is deposited in the liver and
kidneys [45-48] as well as muscle in cattle [48] during
the initial distribution phase. Trace amounts have been
detected in the plasma of sheep up to four weeks after
treatment [47]. This likely accounts for the overall effi-
cacy of IMD for certain hemoprotozoan parasites, but
makes it difficult to compare in vitro IC50 results with
circulating IMD concentrations to determine if ade-
quate drug concentrations are reached in the plasma.
Additionally, the minimum detectable concentration of10 100
tion
(   M)
94. Each point on the nonlinear regression curve represents the mean
ncentration resulting in 50% of the maximum PPE detected in wells
iant 1 (red).
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the previous study [39] exceeded the IC50 of IMD for
both FL and TX observed in the current study. There-
fore, it is possible that the plasma concentration re-
mains higher than the IC50 for a period longer than
that suggested by the previous pharmacokinetics study.
The 2.4 mg/kg dose used in that study was less than
the 4 mg/kg dose currently recommended for clearance
of T. equi [4,7]. Although the higher dose would be ex-
pected to achieve higher plasma concentrations, the
fact that treatment failures occur at the higher dose indi-
cates that IMD plasma concentrations above the IC50 are
not always adequate for elimination of T. equi in vivo.
We observed that the IC50 for the FL strain could be
further increased in vitro by exposure to IMD, as has
been shown previously in vitro for B. bovis [22]. This
finding suggests that resistance could emerge in natural
parasite populations with exposure to IMD when ani-
mals are treated, particularly if complete inhibition of
parasite growth cannot be achieved. As previously men-
tioned, trace amounts of IMD can be found in the
plasma of sheep up to four weeks following treatment
with IMD [47], which could result in prolonged drug se-
lection pressure if the same occurs in horses. Although
horses are not currently treated routinely in the United
States, treatment occurs much more frequently in en-
demic countries. In these endemic countries the goal of
therapy is to treat clinical disease rather than eliminate
the parasite entirely from the host [49]. Therefore, trea-
ted horses can remain chronically infected and retain a
population of parasites that was exposed to IMD yet was
not killed by the drug. The possibility of developing
IMD resistance is concerning, as there are very few op-
tions currently available for treatment of T. equi. In con-
trast to the observations with the FL strain however,
IMD susceptibility in the TX isolate was not altered des-
pite repeated IMD exposure. Thus, the capacity for drug
exposure-associated changes in in vitro IMD susceptibil-
ity varies among T. equi strains. The underlying mech-
anism of IMD resistance among different T. equi strains
is a focus of ongoing investigation.
The BKIs represent a novel class of compounds with
potential as safe and effective treatment alternatives for
T. equi infection, particularly for horses infected with a
strain that is less susceptible to IMD. Compound 1294 is
safe in vivo in rodents and effective against T. gondii
[30], C. parvum [32], P. falciparum [29] and B. bovis [33].
Importantly, it is nontoxic in mice following twice daily
oral administration of 100 mg/kg for five days [29]. It
has 91% oral bioavailability in rats and is likely cleared
by hepatic metabolism [29]. In the current study, this
compound demonstrated equal and substantial efficacy
in vitro against both the TX isolate and the FL Exp vari-
ant 1, which had an almost 15-fold difference in IMDsusceptibility. Importantly, BKI 1294 resulted in com-
plete parasite growth inhibition for both isolates, con-
sistent with its novel mechanism of action. Although
the IC50 of BKI 1294 was higher than that of IMD
in vitro, its apicomplexan-selective target and its favor-
able pharmacokinetics and safety in other mammals
[28-30] suggest that it could be useful for eliminating
T. equi infection in horses. Further investigation of this
class of compounds for this purpose is a focus of on-
going research.
Flow cytometry has been used to evaluate parasite in-
fection of erythrocytes for multiple hemoprotozoan spe-
cies, including B. bovis [50], Anaplasma marginale [51],
B. gibsoni [52], B. canis [53], and P. berghei [54]. This
technique relies on staining of infected erythrocyte pop-
ulations with hydroethidine, which is taken up by live
parasites within intact erythrocytes and converted to the
fluorochrome ethidium bromide. Ethidium bromide in-
tercalates into the DNA of viable parasites and can be
utilized to differentiate infected erythrocytes from those
that are uninfected or that contain non-viable parasites
using flow cytometry [50]. It is therefore particularly
relevant for assessment of drug susceptibility as only
viable parasites are identified, in comparison to the trad-
itional method of evaluating PPE by blood smear in
which parasite viability cannot be determined. In this
study, we were able to successfully apply this technique
for T. equi-infected erythrocytes for the first time to
evaluate parasite growth in drug susceptibility assays.
Conclusions
This study demonstrated variation in IMD susceptibility
for the first time in vitro between two T. equi strains,
with decreased susceptibility and incomplete parasite in-
hibition for the USDA FL strain. This finding was con-
sistent with the inability of IMD to clear the same strain
in vivo in four experimentally infected ponies, despite
two rounds of treatment. Importantly, the emergence of
IMD resistance during exposure to the drug was demon-
strated in vitro. In contrast, no such in vitro variation in
susceptibility between strains was observed for BKI com-
pound 1294. This novel class of compounds may repre-
sent an effective alternative for the treatment of resistant
T. equi infections in horses.
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